Martin Farlow, MD
Neurology · Indianapolis, INNPI 1508880022
Payments from drug & device makers
Across 666 payments — averaging $7228.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$1.5M
- Biogen$829K
- Janssen Research & Development, LLC$643K
- AbbVie$607K
- Novartis$520K
- Eli Lilly$398K
- plus $354K from 11 others
Across 6 payments — averaging $909.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Eli Lilly$2K
- AbbVie$124
What the payments were for
- Consulting fees$145,97999%
- Travel & lodging$1,1481%
- Food & beverage$7431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 406 | $1,463,933 |
| Biogen | 21 | $828,547 |
| Janssen Research & Development, LLC | 62 | $643,387 |
| AbbVie | 78 | $607,300 |
| Novartis | 5 | $519,752 |
| Eli Lilly | 33 | $397,852 |
| F. Hoffmann-la Roche AG | 7 | $131,883 |
| E.r. Squibb & Sons, L.L.C. | 1 | $58,424 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $45,957 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30,860 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 18 | $27,325 |
| Avanir Pharmaceuticals, Inc. | 12 | $23,804 |
| Merz North America, Inc. | 3 | $12,500 |
| Genentech, Inc. | 4 | $10,537 |
| Merck | 6 | $8,513 |
| Novo Nordisk | 3 | $3,740 |
| Axsome Therapeutics, Inc. | 1 | $119 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,814,433 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 142 | $33,856 |
| Memantine Hcl | 312 | $14,658 |
| Donepezil Hcl | 598 | $8,197 |
| Duloxetine Hcl | 109 | $4,114 |
| Escitalopram Oxalate | 260 | $2,771 |
| Mirtazapine | 95 | $2,017 |
| Quetiapine Fumarate | 121 | $1,545 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 29 | $1,228 |
| Solifenacin Succinate | 16 | $1,055 |
| Olanzapine | 29 | $637 |
| Bupropion XlBupropion Hcl | 17 | $518 |
| Bupropion Hcl SrBupropion Hcl | 23 | $480 |
| Levetiracetam | 21 | $463 |
| Sertraline Hcl | 28 | $374 |
| Gabapentin | 33 | $356 |
Paid to pharmacies, not to this prescriber.
Other neurology in Indianapolis
- Kristi GeorgeIndianapolis$10.8M
- Craig HerrmanIndianapolis$7.8M
- Jared BroschIndianapolis$4.7M
- Alexandru BarboiIndianapolis$1.9M
- Kathryn NevelIndianapolis$1M
- Liana ApostolovaIndianapolis$990K
- Robert PascuzziIndianapolis$582K
- Adam ComerIndianapolis$382K
- Cynthia BodkinIndianapolis$377K
- Sarah ZauberIndianapolis$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.